Concert Pharmaceuticals Overview
- Founded
- 2006
- Status
- Public
- Employees
- 64
- Stock Symbol
- CNCE
- Share Price
- $3.95
- (As of Friday Closing)
Concert Pharmaceuticals General Information
Description
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Contact Information
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 65 Hayden Avenue
- Suite 3000N
- Lexington, MA 02421
- United States
+1 (781) 000-0000
Concert Pharmaceuticals Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.95 | $3.45 | $2.57 - $4.62 | $144M | 36.3M | 81.9K | -$2.66 |
Concert Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (10,241) | 18,264 | 276,470 | 109,376 |
| Revenue | 32,573 | 32,578 | 7,902 | 1,077 |
| EBITDA | (93,702) | (78,572) | (73,246) | (76,466) |
| Net Income | (95,110) | (80,051) | (74,766) | (78,166) |
| Total Assets | 129,411 | 165,316 | 159,263 | 137,471 |
| Total Debt | 14,790 | 15,065 | 15,996 | 16,264 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Concert Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.
Request a free trialConcert Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.
Request a free trialConcert Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop smal
Biotechnology
Lexington, MA
64
As of 2021
00000
000000000
00000
00000
magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000000000000
Cambridge, MA
000
As of 0000
00000
000000&0
000000 0
derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000 000000000
Boston, MA
0000
As of 0000
00.000
000
0000-00-00
000000&0
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialConcert Pharmaceuticals Competitors (39)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agios | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 | |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 0000 | 00.000 | 000000&0 | |
| 0000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
| 000000 000 0 | Venture Capital-Backed | Rehovot, Israel | 0 | 000.00 | 0000000000 0 | 000.00 |
Concert Pharmaceuticals Patents
Concert Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020219797-A1 | Process for preparing enantiomerically enriched jak inhibitors | Pending | 06-Feb-2019 | 0000000000 | |
| CA-3129096-A1 | Process for preparing enantiomerically enriched jak inhibitors | Pending | 06-Feb-2019 | 0000000000 | |
| CA-3124399-A1 | Deuterated forms and derivatives of volinanserin | Pending | 21-Dec-2018 | 0000000000 | |
| AU-2019403391-A1 | Deuterated forms and derivatives of volinanserin | Pending | 21-Dec-2018 | 0000000000 | |
| EP-3897507-A1 | Deuterated forms and derivatives of volinanserin | Pending | 21-Dec-2018 | C07B59/002 |
Concert Pharmaceuticals Executive Team (9)
Concert Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christine van Heek | Concert Pharmaceuticals | Board Member | 000 0000 |
| Jesper Hoiland | Self | Board Member | 000 0000 |
| Peter Hutt JD | Self | Board Member | 000 0000 |
| Richard Aldrich | Self | Chairman & Founder | 000 0000 |
| Ronald Barrett Ph.D | Self | Board Member | 000 0000 |
Concert Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialConcert Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.
Request a free trial